All In Biotech

Drug Trial Radar · NCT04995159

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Evaluate the Safety and Efficacy of Optimized Antiplatelet Therapy in Patients With Coronary Heart Disease After Implantation of NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System.

Last checked: Nov 20, 2026Latest source record: Aug 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 2,150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,150

Planned (sponsor's estimate)

Start

Sep 2021

Primary completion

Jan 2026

Study completion Jan 2028

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.

Conditions

  • Coronary Heart Disease

Interventions

  • Single anti-platelet therapyDrug

    Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.

  • Dual anti-platelet therapyDrug

    Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Net adverse clinical event (NACE)Time frame: 3 years

Locations

114 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital with Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Anzhen Hospital, Capital Medical University-12 Ward

    Beijing, Beijing Municipality, China

  • Beijing Anzhen Hospital, Capital Medical University-28 Ward

    Beijing, Beijing Municipality, China

  • Beijing Anzhen Hospital, Capital Medical University-33 Ward

    Beijing, Beijing Municipality, China

  • Beijing Shijitan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Xuan Wu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Jingmei Group General Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Foshan First People's Hospital

    Foshan, Guangdong, China

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Guangdong Medical University

    Guangzhou, Guangdong, China

  • Shantou Central Hospital

    Shantou, Guangdong, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • The Second Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen University General Hospital

    Shenzhen, Guangdong, China

  • Zhanjiang Central People's Hospital

    Zhanjiang, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, China

  • Guilin People's Hospital

    Guilin, Guangxi, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First People's Hospital of Nanning

    Nanning, Guangxi, China

  • Yulin First People's Hospital

    Yulin, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Haikou People's Hospital

    Haikou, Hainan, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • Sanya Central Hospital (Hainan Third People's Hospital)

    Sanya, Hainan, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Hengshui People's Hospital

    Hengshui, Hebei, China

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.